ConductScience.org, home

Paper2644532

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Fisher B and 9 others. N Engl J Med, 1989. Cited by 1,326 papers, by iCite.

Cite this record

ConductScience Library. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. Papers, record 2644532. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2644532

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
PubMed
Journal
N Engl J Med
PubMed
Year
1989
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
1,326
iCite
Relative citation ratio, by iCite
39.4
iCite
Revised in PubMed
2022-03-11
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fisher BB
2Costantino JJ
3Redmond CC
4Poisson RR
5Bowman DD
6Couture JJ
7Dimitrov NVN V
8Wolmark NN
9Wickerham DLD L
10Fisher ERE R

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Lymph NodesMajor topic
Receptors, EstrogenMajor topic
TamoxifenMajor topic
Adult
Aged
Analysis of Variance
Clinical Trials as Topic
Combined Modality Therapy
Double-Blind Method
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Neoplasm Recurrence, Local
Postoperative Care
Random Allocation
Receptors, Progesterone

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
U10-CA-12027NCI NIH HHSUnited StatesU10CA012027PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by293

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,326 citations.

PMIDTitleJournalYearIn PapersSource
42804883Performance of large language models in ambiguous treatment scenarios of early breast cancer.Breast2026https://conductscience.org/library/papers/42804883PubMed
42290019Oncotype DX: Clinical Utility, Evidence, and Future Trends in Personalized Breast Cancer Management.Int J Cancer2026https://conductscience.org/library/papers/42290019PubMed
42157433Multidimensional Cellular Micro-Compartments to Model Invasive Lobular Carcinoma Dormancy.Adv Healthc Mater2026https://conductscience.org/library/papers/42157433PubMed
41634433Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/41634433PubMed
41559081Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice.Nat Commun2026https://conductscience.org/library/papers/41559081PubMed
41398127Physician Partnerships and Adverse Outcomes among Breast Cancer Survivors: The Role of Adherence to Adjuvant Hormone Therapy.J Gen Intern Med2026https://conductscience.org/library/papers/41398127PubMed
40275985Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action.Oncol Rev2025https://conductscience.org/library/papers/40275985PubMed
40099018Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer.Biologics2025https://conductscience.org/library/papers/40099018PubMed
39144911An Unusual Occurrence of Tamoxifen-Induced Maculopathy in a Young Woman With Hormone Receptor-Positive Post-mastectomy Breast Carcinoma.Cureus2024https://conductscience.org/library/papers/39144911PubMed
38291801Prolonged tamoxifen-enriched diet is associated with cardiomyopathy and nutritional frailty in mice.Exp Physiol2024https://conductscience.org/library/papers/38291801PubMed
38116321Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/38116321PubMed
38097623Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer.NPJ Breast Cancer2023https://conductscience.org/library/papers/38097623PubMed
37783846Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.Nat Rev Endocrinol2024https://conductscience.org/library/papers/37783846PubMed
37583424Targeting nuclear hormone receptors for the prevention of breast cancer.Front Med (Lausanne)2023https://conductscience.org/library/papers/37583424PubMed
37380659Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.NPJ Breast Cancer2023https://conductscience.org/library/papers/37380659PubMed
37290594Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma.Biochem Pharmacol2023https://conductscience.org/library/papers/37290594PubMed
36987503Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk.Breast Cancer (Dove Med Press)2023https://conductscience.org/library/papers/36987503PubMed
36755288Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer.Cancer Metab2023https://conductscience.org/library/papers/36755288PubMed
35642027The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation.BMC Pharmacol Toxicol2022https://conductscience.org/library/papers/35642027PubMed
35550274
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study.
Lancet Oncol2022https://conductscience.org/library/papers/35550274PubMed

See all 293 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2644532

GET https://conductscience.org/api/papers/v1/2644532/cited_by?page=2